A 62-year-old man with multiple myeloma (IgG kappa) and a 55-year-old woman with light-chain myeloma (lambda) both present with renal dysfunction. Which finding best distinguishes the renal pathology between these two light-chain types?

Question

Accepted Answer

A. Lambda light chains are more nephrotoxic and cause cast nephropathy more frequently than kappa. ## Light-Chain Type and Renal Pathology in Multiple Myeloma

### Pathophysiology of Light-Chain Nephropathy

**Key Point:** Lambda light chains are **significantly more nephrotoxic** than kappa light chains. Lambda chains are more prone to polymerization and aggregation in the renal tubule, leading to **cast nephropathy (myeloma kidney)** — the most common renal manifestation of light-chain myeloma.

### Comparison of Kappa vs. Lambda Nephrotoxicity

| Feature | Kappa Light Chains | Lambda Light Chains |
| --- | --- | --- |
| **Nephrotoxicity** | Lower | **Higher (2–3× more toxic)** |
| **Propensity to polymerize** | Low | **High** |
| **Primary renal lesion** | Cast nephropathy (less common) | **Cast nephropathy (common)** |
| **Glomerular involvement** | Rare | Possible (AL amyloidosis, light-chain deposition disease) |
| **Frequency of renal failure** | ~20–30% | **~40–50%** |
| **Reversibility with treatment** | Better | Poorer (fibrosis develops faster) |

### High-Yield Facts

**High-Yield:** Lambda light-chain myeloma carries a **worse renal prognosis** than kappa. This is because:
1. Lambda chains have a higher isoelectric point and are more likely to precipitate in the acidic tubular environment.
2. Lambda chains form **casts more readily** in the distal tubule and collecting duct.
3. **Cast nephropathy** (myeloma kidney) is the hallmark renal lesion in light-chain myeloma, and lambda is the predominant culprit.

### Mechanism of Cast Nephropathy

```mermaid
flowchart TD
  A[Light-chain overproduction]:::outcome --> B{Kappa or Lambda?}:::decision
  B -->|Kappa| C[Lower polymerization tendency]:::action
  B -->|Lambda| D[Higher polymerization tendency]:::action
  C --> E[Mild tubular injury, less cast formation]:::outcome
  D --> F[Rapid aggregation in distal tubule]:::action
  F --> G[Cast formation + tubular obstruction]:::outcome
  G --> H[Acute kidney injury, chronic renal failure]:::urgent
```

### Clinical Pearl

**Clinical Pearl:** A patient with light-chain myeloma and acute renal failure should be assumed to have **lambda light chains until proven otherwise**. Kappa light-chain disease is less likely to present with severe renal dysfunction.

### Mnemonic

**Mnemonic:** **"Lambda = Lethal to kidneys"** — Lambda light chains are more likely to cause cast nephropathy and progressive renal failure in myeloma patients.

Answer

B. Kappa light chains cause acute tubular necrosis; lambda causes cast nephropathy

Answer

C. Both cause identical renal histology; the distinction is clinical presentation only

Answer

D. Kappa light chains are filtered more readily and cause glomerulonephritis; lambda causes interstitial fibrosis

A 62-year-old man with multiple myeloma (IgG kappa) and a 55-year-old woman with light-chain myeloma (lambda) both present with renal dysfunction. Which finding best distinguishes the renal pathology between these two light-chain types?

Explanation

Light-Chain Type and Renal Pathology in Multiple Myeloma

Pathophysiology of Light-Chain Nephropathy

Comparison of Kappa vs. Lambda Nephrotoxicity

High-Yield Facts

Mechanism of Cast Nephropathy

Clinical Pearl

Mnemonic

Practice similar questions

Join our NEET PG community

Feature	Kappa Light Chains	Lambda Light Chains
Nephrotoxicity	Lower	Higher (2–3× more toxic)
Propensity to polymerize	Low	High
Primary renal lesion	Cast nephropathy (less common)	Cast nephropathy (common)
Glomerular involvement	Rare	Possible (AL amyloidosis, light-chain deposition disease)
Frequency of renal failure	~20–30%	~40–50%
Reversibility with treatment	Better	Poorer (fibrosis develops faster)